Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Saved in:
| Title: | Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. |
|---|---|
| Authors: | Paz-Ares L; Hospital Universitario 12 de Octubre & Universidad Complutense, Madrid, Spain. Electronic address: lpazaresr@seom.org., Veillon R; CHU Bordeaux, Service des Maladies Respiratoires, Bordeaux, France., Majem M; Hospital de la Santa Creu I Sant Pau, Barcelona, Spain., Zhou C; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China., Tang KJ; Division of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Kim SW; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Richardson G; Cabrini Medical Centre, Malvern, Australia., Girard N; Institut du Thorax Curie-Montsouris, Paris and Paris-Saclay University, UVSQ, Versailles, France., Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute of Oregon, Portland, OR, USA., Mansfield AS; Mayo Clinic, Rochester, MN, USA., Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schuchard J; Johnson & Johnson, Horsham, PA, USA., Diels J; Johnson & Johnson, Beerse, Belgium., Sermon J; Johnson & Johnson, Beerse, Belgium., Bhattacharya A; Johnson & Johnson, High Wycombe, UK., Lorenzini P; Johnson & Johnson, Spring House, PA, USA., Wortman-Vayn H; Johnson & Johnson, Raritan, NJ, USA., Knoblauch RE; Johnson & Johnson, Spring House, PA, USA., Agrawal T; Johnson & Johnson, Spring House, PA, USA., Baig M; Johnson & Johnson, Raritan, NJ, USA., Ono A; Shizuoka Cancer Center, Shizuoka, Japan., Sabari JK; NYU Langone Health, New York, NY, USA. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Mar; Vol. 213, pp. 108788. Date of Electronic Publication: 2025 Oct 03. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
